High Expression of Complement Component C7 Indicates Poor Prognosis of Endometrial Cancer and poor 5-year OS

Abstract

Background: Corpus Carcinoma is the most commonly diagnosed female cancer worldwide. However, the well-known biomarkers are not enough to meet the needs of precision medicine. Novel targets are desirable and highly valuable for improved patient survival. In this regard, we identified complement component C7 as one of the candidates based on data from the TCGA database.Method: C7 expression was examined by mRNA expression profile in 425 cases of corpus carcinoma, including grade 3 data (such as mRNA-seq, miRNA-seq, and clinical data) from 406 primary corpus carcinoma tissues and 19 normal controls from the dataset. The availability of data is demonstrated by heat maps, and the distribution of genes is demonstrated by volcanic maps. Then the value of C7 was demonstrated on the basis of genomics and clinical epidemiology respectively, confirmed by grade 3 data from TCGA. The relationship between the C7 expression and five-year survival of corpus carcinoma patients was analyzed in order to investigate the function of C7 in corpus carcinoma. Result: In our present study, we reported for the first time that C7 was an independent prognostic factor of corpus carcinoma and the 5-year survival rate of patients with high C7 expression is lower than that of patients with low C7 expressions. (p=0.02265) Conclusion: In summary, high expression of C7 may promote corpus carcinoma development. Our present study laid a foundation to help clinicians improve the identification of patients for C7 in the era of precision medicine.